Cancer Science & Therapy

Claudia Cellini

Publications

• Case Report
  Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report
  Author(s): Cinzia Pellegrini, Beatrice Casadei, Claudia Cellini, Lisa Argnani, Michele Cavo and Pier Luigi ZinzaniCinzia Pellegrini, Beatrice Casadei, Claudia Cellini, Lisa Argnani, Michele Cavo and Pier Luigi Zinzani
  
  Background: Nivolumab and pembrolizumab are the first two US FDA-approved monoclonal antibodies targeting PD-1 for Hodgkin lymphoma (HL) and provide promising results in the relapsed/refractory setting (HL patients relapsing after autologous stem cell transplantation [ASCT], or with chemorefractory disease and/ or ineligible for ASCT). An interesting area of ongoing research is the possibility of combining different immune checkpoint inhibitors given concomitantly or sequentially in the attempt to maximize the patient responsiveness. Case report: A heavily pre-treated young woman affected by HL, after several attempts, obtained a complete response after ASCT thanks to the bridge with pembrolizumab. After relapse, the patient achieved again a complete response with nivolumab, bridging her to allotransplant. The patient is still in response to a year since the transplant. Discussion and Co.. Read More»
  DOI: 10.4172/1948-5956.1000534

  Abstract PDF